Nearly two years after its creation, the complex generic drug parallel scientific advice pilot program still has not received enough interest to effectively judge its value.
Complex Generic Sponsors Not Using US FDA-EMA Parallel Scientific Advice Program
After nearly two years, the program has received only two requests, driving FDA officials to try to boost interest.
